Recently, a clinical trial showed that IL-15 can increase CD8+ T cell and NK cell numbers up to 5.8 and 38 times that of the control group, respectively, and 17 of the 27 patients treated with IL-15 showed no tumor progression (59). Here, CD8A is linked to neoplasm.